HER2-positive Breast Cancer Clinical Trials

98 recruitingLast updated: June 17, 2026

There are 98 actively recruiting her2-positive breast cancer clinical trials across 33 countries. Studies span Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


HER2-positive Breast Cancer Trials at a Glance

98 actively recruiting trials for her2-positive breast cancer are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 42 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running her2-positive breast cancer studies include Shu Wang, H. Lee Moffitt Cancer Center and Research Institute, and Dana-Farber Cancer Institute.

Browse her2-positive breast cancer trials by phase

Treatments under study

About HER2-positive Breast Cancer Clinical Trials

Looking for clinical trials for HER2-positive Breast Cancer? There are currently 93 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-positive Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-positive Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 98 trials

Recruiting
Phase 1

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI

HER2-positive Breast Cancer
University of Alabama at Birmingham25 enrolled1 locationNCT04332588
Recruiting
Phase 2

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

HER2-positive Breast Cancer
The First Affiliated Hospital of Soochow University124 enrolled1 locationNCT07647263
Recruiting
Phase 2Phase 3

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

HER2-positive Breast Cancer
Hoffmann-La Roche650 enrolled55 locationsNCT07413939
Recruiting
Phase 3

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.596 enrolled2 locationsNCT07518173
Recruiting

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer

HER2-positive Breast Cancer
Centre Paul Strauss9,000 enrolled1 locationNCT04638725
Recruiting
Phase 2

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital182 enrolled1 locationNCT07635342
Recruiting
Not Applicable

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University20 enrolled1 locationNCT07616440
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Breast CancerHER2-positive Breast CancerBreast Cancer Stage IV
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT07459673
Recruiting
Phase 2

Study of Screening Brain MRIs in Stage IV Breast Cancer

Triple-Negative Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute170 enrolled2 locationsNCT05115474
Recruiting
Phase 2

A Study of Surgery and Radiotherapy in People With Breast Cancer

Metastatic Breast CancerHER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center178 enrolled7 locationsNCT07053085
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled26 locationsNCT07102381
Recruiting
Phase 2

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute500 enrolled53 locationsNCT04893109
Recruiting
Phase 1

HER2 Vaccine for Locally Advanced Breast Cancer

Breast CancerHER2-positive Breast Cancer
Pravin T.P Kaumaya36 enrolled1 locationNCT06949410
Recruiting

Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients

HER2-positive Breast Cancer
Giampaolo Bianchini10 enrolled1 locationNCT06518382
Recruiting
Phase 3

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460
Recruiting
Phase 2

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Triple-Negative Breast CancerHER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802